TriangleNCT02663518 · OUTCOME
Part 4: Percentage of CD47 Receptor Occupancy on Peripheral Blood CD3+ Cells
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- Percentage of cells
- Interval / dispersion
- Standard Deviation
- Time frame
- Part 4: Week 1 end of infusion (EOI)
What was measured
CD47 is a cell-surface protein expressed on multiple normal cell types and often at high levels on many malignant tumor cells.
Analysis population: Safety population included all the participants who received at least one dose of study treatment. Here, "Number of Participants Analyzed" signifies number of participants evaluable for this outcome measure.
Groups in this outcome
Part 4: Ontorpacept (PF-07901800/TTI-621) 0.5 mg/kg
Participants with relapsed or refractory CTCL received TTI-621 0.5 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
Part 4: Ontorpacept (PF-07901800/TTI-621) 0.7 mg/kg
Participants with relapsed or refractory CTCL received TTI-621 0.7 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
Part 4: Ontorpacept (PF-07901800/TTI-621) 1.0 mg/kg
Participants with relapsed or refractory CTCL received TTI-621 1.0 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
Part 4: Ontorpacept (PF-07901800/TTI-621) 1.4 mg/kg
Participants with relapsed or refractory CTCL received TTI-621 1.4 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
Part 4: Ontorpacept (PF-07901800/TTI-621) 2.0 mg/kg
Participants with relapsed or refractory CTCL received TTI-621 2.0 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
Part 4: Ontorpacept (PF-07901800/TTI-621) Q2W / 2.0 mg/kg
Participants with relapsed or refractory CTCL received a 2.0 mg/kg TTI-621 infusion once every 2 weeks until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
| Group | Source count |
|---|---|
| Part 4: Ontorpacept (PF-07901800/TTI-621) 0.5 mg/kg | 3 |
| Part 4: Ontorpacept (PF-07901800/TTI-621) 0.7 mg/kg | 3 |
| Part 4: Ontorpacept (PF-07901800/TTI-621) 1.0 mg/kg | 3 |
| Part 4: Ontorpacept (PF-07901800/TTI-621) 1.4 mg/kg | 4 |
| Part 4: Ontorpacept (PF-07901800/TTI-621) 2.0 mg/kg | 5 |
| Part 4: Ontorpacept (PF-07901800/TTI-621) Q2W / 2.0 mg/kg | 3 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 4: Ontorpacept (PF-07901800/TTI-621) 0.5 mg/kg | 62.25 | 12.65 | Not reported | Not reported | Not reported |
| Part 4: Ontorpacept (PF-07901800/TTI-621) 0.7 mg/kg | 65.49 | 24.80 | Not reported | Not reported | Not reported |
| Part 4: Ontorpacept (PF-07901800/TTI-621) 1.0 mg/kg | 37.17 | 32.93 | Not reported | Not reported | Not reported |
| Part 4: Ontorpacept (PF-07901800/TTI-621) 1.4 mg/kg | 57.09 | 23.72 | Not reported | Not reported | Not reported |
| Part 4: Ontorpacept (PF-07901800/TTI-621) 2.0 mg/kg | 65.00 | 5.97 | Not reported | Not reported | Not reported |
| Part 4: Ontorpacept (PF-07901800/TTI-621) Q2W / 2.0 mg/kg | 49.51 | 10.83 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 12.65
- value
- 62.25
- group Id
- OG001
- spread
- 24.80
- value
- 65.49
- group Id
- OG002
- spread
- 32.93
- value
- 37.17
- group Id
- OG003
- spread
- 23.72
- value
- 57.09
- group Id
- OG004
- spread
- 5.97
- value
- 65.00
- group Id
- OG005
- spread
- 10.83
- value
- 49.51
- denoms
- counts
- group Id
- OG000
- value
- 3
- group Id
- OG001
- value
- 3
- group Id
- OG002
- value
- 3
- group Id
- OG003
- value
- 4
- group Id
- OG004
- value
- 5
- group Id
- OG005
- value
- 3
- units
- Participants
- description
- CD47 is a cell-surface protein expressed on multiple normal cell types and often at high levels on many malignant tumor cells.
- dispersion Type
- Standard Deviation
- groups
- description
- Participants with relapsed or refractory CTCL received TTI-621 0.5 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
- id
- OG000
- title
- Part 4: Ontorpacept (PF-07901800/TTI-621) 0.5 mg/kg
- description
- Participants with relapsed or refractory CTCL received TTI-621 0.7 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
- id
- OG001
- title
- Part 4: Ontorpacept (PF-07901800/TTI-621) 0.7 mg/kg
- description
- Participants with relapsed or refractory CTCL received TTI-621 1.0 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
- id
- OG002
- title
- Part 4: Ontorpacept (PF-07901800/TTI-621) 1.0 mg/kg
- description
- Participants with relapsed or refractory CTCL received TTI-621 1.4 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
- id
- OG003
- title
- Part 4: Ontorpacept (PF-07901800/TTI-621) 1.4 mg/kg
- description
- Participants with relapsed or refractory CTCL received TTI-621 2.0 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
- id
- OG004
- title
- Part 4: Ontorpacept (PF-07901800/TTI-621) 2.0 mg/kg
- description
- Participants with relapsed or refractory CTCL received a 2.0 mg/kg TTI-621 infusion once every 2 weeks until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
- id
- OG005
- title
- Part 4: Ontorpacept (PF-07901800/TTI-621) Q2W / 2.0 mg/kg
- param Type
- MEAN
- population Description
- Safety population included all the participants who received at least one dose of study treatment. Here, "Number of Participants Analyzed" signifies number of participants evaluable for this outcome measure.
- reporting Status
- POSTED
- time Frame
- Part 4: Week 1 end of infusion (EOI)
- title
- Part 4: Percentage of CD47 Receptor Occupancy on Peripheral Blood CD3+ Cells
- type
- SECONDARY
- unit Of Measure
- Percentage of cells
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice